Your browser is no longer supported. Please, upgrade your browser.
Settings
SNY Sanofi daily Stock Chart
SNY [NYSE]
Sanofi
Index- P/E20.48 EPS (ttm)1.88 Insider Own16.40% Shs Outstand2.64B Perf Week0.23%
Market Cap101.64B Forward P/E12.15 EPS next Y3.17 Insider Trans0.00% Shs Float2.30B Perf Month-6.15%
Income4.94B PEG2.89 EPS next Q0.75 Inst Own9.70% Short Float0.12% Perf Quarter3.40%
Sales38.42B P/S2.65 EPS this Y4.10% Inst Trans0.18% Short Ratio1.31 Perf Half Y-8.48%
Book/sh25.10 P/B1.53 EPS next Y0.16% ROA- Target Price52.00 Perf Year-22.18%
Cash/sh- P/C- EPS next 5Y7.10% ROE- 52W Range36.11 - 52.76 Perf YTD-6.06%
Dividend1.66 P/FCF- EPS past 5Y-4.40% ROI6.50% 52W High-26.19% Beta1.01
Dividend %4.32% Quick Ratio- Sales past 5Y0.50% Gross Margin68.80% 52W Low7.83% ATR0.95
Employees115631 Current Ratio- Sales Q/Q-3.60% Oper. Margin- RSI (14)43.95 Volatility2.17% 1.48%
OptionableYes Debt/Eq- EPS Q/Q4.60% Profit Margin- Rel Volume4.47 Prev Close38.45
ShortableYes LT Debt/Eq- EarningsJul 29 BMO Payout- Avg Volume2.06M Price38.94
Recom2.30 SMA20-2.76% SMA50-3.34% SMA200-6.16% Volume6,659,659 Change1.27%
May-03-16Downgrade HSBC Securities Buy → Hold
Dec-10-15Downgrade Exane BNP Paribas Neutral → Underperform
Dec-01-15Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-09-15Downgrade Bernstein Outperform → Mkt Perform
Oct-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-22-15Upgrade Citigroup Sell → Neutral
Apr-15-15Initiated Societe Generale Buy
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
Aug-28-09Upgrade JP Morgan Neutral → Overweight
Jun-29-09Downgrade JP Morgan Overweight → Neutral
May-28-09Upgrade Citigroup Hold → Buy
Apr-30-09Upgrade JP Morgan Neutral → Overweight
Mar-23-09Upgrade Jefferies & Co Underperform → Hold
Mar-17-09Initiated Credit Suisse Outperform
Feb-19-09Upgrade JP Morgan Underweight → Neutral
Jan-26-09Initiated Jefferies & Co Underperform
Nov-07-08Downgrade UBS Neutral → Sell
Jun-27-16 12:23PM  Novo Nordisks Premium Valuation Based on Price-to-Earnings
11:52AM  As Old Bestsellers Plateau, a Look at 4 Next Generation Diabetes Drugs at Insider Monkey
08:15AM  Sanofi Inks Deal to Swap Business with Boehringer Ingelheim
04:51AM  Sanofi to Exit Animal Care in $25 Billion Asset Swap With Boehringer
01:36AM  Sanofi, Boehringer Ingelheim Agree to $25 Billion Asset Swap
Jun-25-16 12:05PM  How Was Roches Operational Performance in 2Q16?
Jun-24-16 05:00PM  MannKind Will Market Afrezza Better Than Sanofi Ever Did at Forbes -6.65%
02:19PM  Glass Lewis urges Medivation shareholders to support current board
10:02AM  MannKind Corp. Shares Are Down 28.3% So Far This Year. Here's Why. at Motley Fool
Jun-23-16 05:01PM  Sanofi's Likely Sweetener for Medivation Panned
09:24AM  $18,543 Invested in This Biotech a Decade Ago Is Now Worth $1 Million at Motley Fool
07:56AM  New Four-Strain Influenza Vaccine, VaxigripTetra, Regulatory Dossier from Sanofi Pasteur Now Approved in Europe PR Newswire
Jun-22-16 11:05PM  Sanofi Pasteur Dengue Vaccine Approved in Costa Rica PR Newswire
01:46PM  Sanofi Said to Consider Adding Future Payments to Medivation Bid at Bloomberg
12:20PM  The Top Four Diabetes Best Sellers and One Oral Insulin Pill That May Threaten Them All at Insider Monkey
07:23AM  Warren Buffett's Favorite High-Yield Dividend Stock at Motley Fool
Jun-21-16 05:40PM  Why Biogen Inc. Is Down 22.5% In 2016 at Motley Fool
03:03PM  7 Pharmaceutical Stocks With Dividends Yielding More Than 3% at Motley Fool
01:06PM  [$$] Inovio Zika Vaccine Clear for Human Study at Barrons.com
09:05AM  How Inovio Pharmaceuticals Is Leading the Zika Vaccine Race at Motley Fool
Jun-20-16 08:57AM  Biotech stocks are in for more election trouble on drug pricing at MarketWatch
05:25AM  BioMed Realty exec on why Kendall Square lab space is still in such demand at bizjournals.com
05:00AM  Visium Insider-Trading Scheme Brought Down by Tip on Mismarking
05:00AM  Visium Insider-Trading Scheme Brought Down by Mismarking Tip at Bloomberg
Jun-17-16 12:25PM  BioMarin Takeout Rumors Swirl, Industry Insiders Aren't Convinced
Jun-16-16 01:45PM  Visium Hedge Fund Partner Charged in Insider Trading Case
Jun-15-16 04:46PM  Relypsa Sales Numbers Surprise to the Upside
Jun-14-16 10:00PM  ADVA launches Dengue Mission Buzz Barometer tool to boost critical dengue prevention awareness and preparedness amongst ASEAN Community PR Newswire
11:01AM  Regeneron: Nine Reasons Praluent Could Be Forced From the US Market at Barrons.com
09:00AM  Medivation Has a Good Case for Patience at Bloomberg
Jun-13-16 05:01PM  Medivation Urges Shareholders to Reject Sanofi Proposal
12:50PM  UPDATE 1-Sanofi, Medivation advance to next phase of takeover fight Reuters
12:07PM  ETFs with exposure to Sanofi : June 13, 2016
09:33AM  Sanofi files request to replace Medivation board Reuters
09:28AM  Sanofi to Approach Medivation Shareholders to Replace Board at Bloomberg
Jun-12-16 03:54PM  Sanofi Announces Positive Phase 3 Results for Investigational Titratable Fixed-Ratio Combination of Insulin Glargine and Lixisenatide PR Newswire
03:45PM  Sanofi says LixiLan diabetes drug trials meet targets Reuters
Jun-11-16 11:01AM  Successful Switch to Sanofi's Toujeo® Evaluated in a Real-World Setting PR Newswire
11:01AM  Successful Switch to Sanofi's Toujeo® Evaluated in a Real-World Setting CNW Group
Jun-08-16 05:18PM  GlaxoSmithKline PLC (ADR) (GSK) Poised To Overtake Sanofi SA (ADR) (SNY) In This $1.8 Billion Market at Insider Monkey
09:45AM  ANTB: Once Weekly Diabetes Therapy: Investors Needed
07:37AM  Sanofi hopes to oust Medivation's board by August 1
Jun-07-16 07:35AM  Boston area tops new report on early stage biotech research, employment at bizjournals.com
Jun-06-16 01:20PM  Relypsa: Largest Institutional Shareholders are Buying More Stock
09:52AM  Regeneron, Sanofi Report Positive Dupilumab Phase III Data
01:27AM  Sanofi and Regeneron report positive skin disease trial Reuters
01:00AM  Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients PR Newswire
Jun-04-16 08:00AM  Sleepy Bedford biotech Anika wakes up investors with recent success at bizjournals.com
Jun-03-16 11:02AM  Pfizer, Sanofi Could Eye Biogen's Hemophilia Franchise
Jun-02-16 03:07PM  Why does Biogen need a sixth drug for multiple sclerosis? at bizjournals.com
01:30PM  What Will It Take for Sanofi to Snag Medivation? $63 a Share at Barrons.com
11:03AM  Alnylam gains a cool $1.5B in market cap on bad news for rival at bizjournals.com
07:35AM  Medivation Pulls Up Shareholder Drawbridge as Sanofi Battle Looms
03:04AM  Changes in Sanofis Profitability in 1Q16
02:53AM  Medivation sets eligibility date for shareholder consent on board revamp
02:52AM  UPDATE 1-Medivation sets eligibility date for shareholder consent on board revamp
Jun-01-16 07:28PM  Medivation sets June 1 deadline for shareholder consent on board revamp
03:19PM  Sanofi requests Medivation set deadline for shareholder consent on board revamp
09:39AM  Bayer, Monsanto have yet to engage in meaningful dialogue...
09:00AM  Top Equity Manager Still Believes In MannKind at Forbes
May-31-16 12:21PM  3 Billionaires Bet on MannKind Stock -- Should You Follow? at Motley Fool
May-28-16 12:15AM  [$$] Medivations Sanofi Strategy May Be in Trouble at The Wall Street Journal
May-27-16 08:05PM  [$$] Medivation May Feel Pressured by Sanofi at The Wall Street Journal
01:20PM  Dealpolitik: Medivation's 'Just Say No' Strategy May Be in Trouble at The Wall Street Journal
11:46AM  Medivation Fires Back Following Sanofi's Board Proposal
10:01AM  Interested in Medivation? Take a Number! at Motley Fool
08:22AM  Better Buy: Regeneron Pharmaceuticals, Inc. vs. Roche at Motley Fool
May-26-16 01:38PM  Could Rally Cool Off Ahead Of Friday's GDP Data and Yellen Speech?
11:35AM  How Medivation Shareholders May Lose Big by Poison Pill in Hostile Takeover Fight With Sanofi at 24/7 Wall St.
10:20AM  Sanofi's Diabetes Drug Combination Wins FDA Panel Backing
12:12AM  [$$] Sanofi Moves to Replace Medivation Board at The Wall Street Journal
May-25-16 06:50PM  FDA Advisory Committee Recommends Approval of Sanofi Treatment for Adults with Type 2 Diabetes PR Newswire
04:59PM  Medivation: Three Biotech Giants Enter. Which One Leaves? at Barrons.com
04:58PM  Stocks climb for the second day as energy companies jump at Los Angeles Times
04:41PM  Sanofi moves to oust Medivation board in $9.3 billion takeover fight Reuters
04:33PM  Sanofi moves to oust Medivation board in $9.3 bln takeover fight Reuters
04:32PM  U.S. panel backs approval of Sanofi combination diabetes drug Reuters
04:08PM  Sanofi Moves To Replace Medivations Board As New Buyers Rumored
03:50PM  Novo Nordisk IDegLira Recommended by FDA Advisory Committee
03:29PM  Alnylam Soars as Drugmakers Circle Rival Biotechnology Company
01:59PM  [$$] Sanofi Moves to Replace Medivation Board at The Wall Street Journal
01:07PM  [$$] Sanofi seeks to oust entire Medivation board at Financial Times
12:38PM  Why Sanofi SA (ADR) (SNY) Is Trending on Wednesday at Insider Monkey
12:02PM  Sanofi Plays Game of Chicken With Medivation at Bloomberg
11:07AM  Major Developments for Sanofi in 1Q16
11:00AM  Sanofi wants to dump Medivation's board after rejected deal
10:48AM  Medivation Advises Its Shareholders To Spurn Sanofi's Move To Replace Entire Board
10:24AM  Sanofi Moves to Oust Medivation Board
09:39AM  Faber Report: Sanofi seeks to replace Medivation board
08:23AM  Celgene, Gilead Said to Join Suitors Mulling Medivation Bids at Bloomberg
07:19AM  Sanofi Seeks to Change Medivation Board as Advances Spurned at Bloomberg
07:00AM  3 High-Quality Stocks to Buy Now at Morningstar
06:58AM  Sanofi names eight candidates to replace Medivation board
05:05AM  French drugmaker Sanofi to step up push into China
01:00AM  Sanofi Genzyme Launches its vs.MS Global Campaign to Address the Physical and Emotional Burden of Multiple Sclerosis Business Wire
12:37AM  Exclusive: Sanofi to unveil challenge to Medivation's board - sources
May-24-16 03:06PM  Sanofis Diabetes and Cardiovascular Franchise Performance
12:24PM  Pfizer's Buyout of Anacor Pharmaceuticals for $5.2 Billion Is a Bad Move -- Here's Why at Motley Fool
11:53AM  Allergan, Inc. (AGN) Receives Good News from Japan at Insider Monkey
11:07AM  How Does Merial Contribute to Sanofis Growth?
Sanofi researches, develops, manufactures, and markets various therapeutic solutions. The company operates in three segments: Pharmaceuticals, Vaccines, and Animal Health. It offers Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; Toujeo, an insulin glargine; and Afrezza, an inhaled insulin. The company also provides Praluent, a human monoclonal antibody; and Multaq, a multichannel blocker with anti-arrhythmic properties. In addition, it offers Cerezyme, an enzyme replacement therapy to treat gaucher disease; cerdelga, an oral therapy for Gaucher disease Type 1; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis Type 1, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for breast, prostate, gastric, lungs, and head and neck cancer treatment; Eloxatin for the treatment of stage III colon cancer; Thymoglobulin to treat acute rejection; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix/Iscover for atherothrombosis and acute coronary syndrome; Lovenox/Clexane for the treatment of venous thromboembolism; Aprovel/Avapro/Karvea for hypertension and nephropathy; Renagel/Renvela to treat chronic kidney disease; Allegra/Telfast to treat seasonal allergic rhinitis and uncomplicated hives; Stilnox/Ambien/Myslee for insomnia treatment; and Synvisc/Synvisc-One for the treatment of osteoarthritis pain. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerJun 14Buy363.8664,73123,552,85923,418,396Jun 16 05:47 PM
Sanofi10% OwnerFeb 17Buy393.7180,00031,496,72823,353,665Feb 18 05:45 PM
Sanofi10% OwnerFeb 16Buy391.2381,15731,751,18223,273,665Feb 18 05:45 PM
Sanofi10% OwnerJan 12Buy465.0483,93839,034,66023,192,508Jan 14 05:46 PM
Sanofi10% OwnerNov 03Buy10.00900,0009,000,0003,218,899Nov 05 02:37 PM
Sanofi10% OwnerOct 06Buy472.3311,0405,214,51923,108,570Oct 08 05:50 PM
Sanofi10% OwnerOct 06Buy459.7180,53837,024,19723,097,530Oct 08 05:45 PM
Sanofi10% OwnerJul 27Buy537.4810,6395,718,27222,869,783Jul 29 05:46 PM